XYMOGEN Reports $5.2 million in Revenue for January

ORLANDO, Fla.XYMOGEN, a nutraceutical company providing dietary supplements,  announced a record of $5.2 million in sales for January.

According to Mike Mahoney, senior vice president at XYMOGEN, the month's sales increased by $2 million compared to January 2012 and even exceeded projections of $4 million. The company also made $1 million more per month  overall.

"The vast majority of January's growth may be attributed to the success of our annual XYMOGEN XPERIENCE in January," said Brian Blackburn, CEO and president of XYMOGEN. "It included a facility tour and a review of XYMOGEN's solid financial foundation, which is essential to funding growth initiatives moving forward."

The company's total revenue last year was $46.5 million, and for 2013, the company is aiming for $59 million in sales and $75 million for 2014.

XYMOGEN currently develops and manufactures dietary supplements such as probiotics, antioxidants, and women's health supplements and formulas that control blood sugar and help against the effects of chemotherapy.

XYMOGEN partnered with Acasti Pharma last year and launched LipiChol540, a physician-prescribed medical food for managing omega-3 phospholipid deficiency.